52 results about "Transplant cell" patented technology

The invention discloses a bionic nanofiber-hydrogel composite biological scaffold as well as a preparation method and application thereof. The bionic nanofiber-hydrogel composite biological scaffold is a composite scaffold for simulating a gray-white matter partition structure of a spinal cord tissue, and comprises bionic nanofibers and a bionic hydrogel material, wherein the bionic nanofibers are arranged in an oriented manner and simulate a white matter ordered structure around the spinal cord, and the bionic hydrogel material is combined with the bionic nanofibers and simulates gray matter in the center of the spinal cord. According to the bionic nanofiber-hydrogel composite biological scaffold, the biological activity of loaded stem cells or adult cells can be improved, the problem that a large number of transplanted exogenous cells die due to unbalanced oxidative stress generated after tissue damage can be solved, and it is guaranteed that the transplanted cells reside in a damaged area and play a role; therefore, the spinal cord microenvironment is improved, proliferation and differentiation of endogenous neural stem cells are promoted, functional recovery after spinal cord injury is finally promoted, and great potential is achieved in spinal cord injury treatment.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

Disclosed herein are devices for encapsulating biological cells and are suitable to be implanted into a subject. In different aspects of the disclosure, the devices may comprise a plurality of polymer layers. In one aspect, a device comprises a first polymer layer and a second polymer layer. In some cases, the first polymer layer may be a nanoporous polymer layer. In some cases, the second polymer layer may be a macroporous polymer layer. The first and second polymer layers may define a lumen for enclosing a population of cells. The devices may be used to transplant cells producing therapeutic agents into a subject (e.g., for the treatment of a disease).

The invention discloses a stem cell-derived function-enhanced mesenchymal stromal cell as well as a preparation method and application thereof. The preparation method comprises the following steps: inserting an IL-10 gene coding sequence and a CD47 gene coding sequence into a human pluripotent stem cell; a neural crest cell differentiation culture medium containing a Wnt pathway agonist and an ALK5 inhibitor is used for carrying out induced differentiation culture on the CD47 positive human pluripotent stem cells to obtain the neural crest cells. The neural crest cells are subjected to induced differentiation culture by adopting a transition culture medium containing an epidermal growth factor, a fibroblast growth factor 2 and a cell apoptosis inhibitor and a mesenchymal stromal cell differentiation culture medium containing the epidermal growth factor, the fibroblast growth factor 2 and a platelet growth factor in sequence; according to the present invention, with the combination of the specific embodiments, the obtained mesenchymal stromal cell highly expresses CD47 and IL-10, the expression of the CD47 can help the transplanted cell escape from the attack of the immune system and prolong the cell survival time, and the expression of the IL-10 can be used for anti-inflammation.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

The embodiment of the present invention discloses an induction culture medium, method and application for improving the viability and factor secretion ability of hair follicle-derived mesenchymal stem cells in a hypoxic environment. The induction culture medium includes a basal culture medium and an induction drug, and the induction drug includes transforming growth factor β, hepatocyte growth factor, cyclic adenosine monophosphate, triptolide, sodium hydrosulfide, lipopolysaccharide, hyaluronic acid, dexamethasone, L-glutamine and HEPES buffer. The induction culture medium provided by the present invention can promote the metabolism and energy production of hair follicle-derived mesenchymal stem cells, enhance the antioxidant capacity of cells, improve the survival rate and factor secretion ability of cells in a hypoxic environment, and solve the problems of low cell viability, slow growth, low cytokine secretion, etc. after transplanting cells into damaged tissue areas in the prior art.

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

The invention discloses a preparation method of a transplantable cell strain for treating Parkinson's disease, which comprises the following steps: injecting pluripotent stem cells into animal body tissues, and inducing through a tissue microenvironment. According to the method, the uniqueness of in-vivo tissues is utilized, so that the stem cells are finally proliferated and differentiated into the nerve-like precursor cells capable of being transplanted for treating the Parkinson's disease, a large number of transplantable cells can be efficiently, conveniently and safely obtained through the method, and the method is used for solving the problem that the source and the number of cells are limited in previous cell transplantation. And a new possibility is provided for treatment of nerve injury diseases.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

The invention relates to the technical field of nerve injury repair, in particular to a spinal cord injury repair system based on ordered collagen scaffold carried cell transplantation combined with electroacupuncture stimulation application. The invention provides a spinal cord injury repairing system, which comprises a biological material support transplanting module, a cell inoculating module and a spinal cord injury repairing module, and the electro-acupuncture stimulation module is used for applying electro-acupuncture stimulation to acupuncture points after the biological material stent inoculated with the cells is transplanted to the spinal cord injury part. According to the system, electroacupuncture stimulation and biomaterial stent transplantation cells are combined for application, the microenvironment can be remarkably improved, survival, differentiation and function integration of the transplantation cells can be promoted, meanwhile, muscle atrophy and joint degeneration are relieved, an innovative treatment system is provided for spinal cord injury, and the system has high clinical feasibility and is worthy of popularization and application. Good application prospects are realized in the field of spinal cord injury repair.

Novel methods are disclosed for treating patients with Parkinson's disease and other primary and secondary parkinsonian disorders by improving cell engraftment. Treating patients with antihyperlipidemic drugs and / or CSF-1R antagonists before, during, and / or after transplantation of DA neurons improves cell viability, engraftment, proliferation, migration, or differentiation of the administered DA neurons. Methods are disclosed for pre-treating patients to improve engraftment of administered cells. Methods are disclosed for pre-treating patients to improve engraftment of administered progenitor cells.

An implantable membrane construct including a maximum pore size (MPS) less than 2 microns and opposing sides, each side of the construct having a surface roughness (Sa) greater than about 0.5 microns is disclosed. When the luminal surface of the implantable membrane construct has a surface roughness (Sa) greater than about 0.5 microns, mesenchymal cells do not form at the interface of the lumen and the first layer (i.e., luminal interface) such that the mesenchymal cells do not impede the flow of oxygen and nutrients to the graft cells (when implanted). When implanted, the outermost layer of the implantable membrane construct enables cellular penetration, vascularization, and anchoring of the construct. The implantable membrane construct includes single layer embodiments and multiple layer embodiments. Encapsulation devices utilizing the implantable membrane constructs to encapsulate biological entities (e.g., cells) into a patient are also provided.

An implantable membrane structure is disclosed that includes a maximum aperture (MPS) of less than 2 microns and opposing sides, each side of the structure having a surface roughness (Sa) of greater than about 0.5 microns. When the surface roughness (Sa) of the lumen surface of the implantable membrane structure is greater than about 0.5 microns, mesenchymal cells do not form at the interface of the lumen and the first side, i.e., the lumen interface, so that the mesenchymal cells do not hinder flow of oxygen and nutrients to transplanted cells (when implanted). When implanted, the outermost layer of the implantable membrane structure enables cell penetration, vascularization, and structural anchoring. The implantable membrane structure includes a single layer embodiment and a multi-layer embodiment. Encapsulation devices for encapsulating biological entities (e.g., cells) into a patient using implantable membrane structures are also provided.

The field of the invention encompasses synthetic chromosome compositions and methods that allow single cell spatiotemporal analysis in response to differentiation cues and labeling of transplanted cells to monitor the fate and function of such cells in the patient recipient.

The purpose is to provide a method for suppressing rejection by NK cells in cells or a tissue for transplantation. Provided is a method for producing cells or a tissue for transplantation, the method comprising a step for expressing, on the surface of cells for transplantation or cells constituting a tissue for transplantation, at least one membrane-type stimulating antibody specific to an inhibitory receptor for NK cells. Preferably, the method comprises a step of expressing a membrane-type stimulating antibody specific to each of one or more, for example, three or more, for example, four inhibitory receptors selected from the group consisting of NKG2A, KIR2DL1, KIR2DL3, KIR3DL1 and LILRB1. The present invention further provides pluripotent stem cells and T cells or progenitor cells thereof in which a gene encoding the membrane-type stimulating antibody is introduced or expressed. The present invention further provides an antibody specific to an inhibitory receptor for NK cells.

Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cells receive insufficient nutrients until they are able to establish a functional microcirculation to support their metabolic and physiological needs after transplantation. Nanoparticles are provided for use in supplying nutrients and other therapeutic agents to transplanted cells to improve cell survival. Such nanoparticles can be used to supply nutrients and other factors to transplanted cells until the transplanted cells are able to develop a new microcirculation.

Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.

Provided herein are methods of inducing immune tolerance to graft cells in a human patient in need thereof comprising administering to the patient (i) the graft cells. (ii) a chimeric FasL protein conjugated to a hydrogel, and (iii) transient sirolimus.

The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.

The invention relates to a myocardial progenitor cell and drug double-loaded hydrogel biological material and application thereof, and particularly provides a biological material compound which comprises an organic compound, living cells and a loading material, and the organic compound can induce expression of protease. The compound is used in the treatment process of myocardial infarction (MI), the functionality of transplanted cells is improved, and effective repair and functional recovery of damaged myocardium are promoted.

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).

The present invention relates to the use of midbrain organoids in the preparation of a medicament for treating Parkinson's disease, wherein the midbrain organoids are derived from pluripotent stem cells and do not contain serotonergic neurons. The present invention discovers for the first time the therapeutic effect of midbrain organoids on Parkinson's disease, which has advantages such as high compatibility compared to the transplanted cells obtained by two-dimensional culture of iPSCs, and has advantages such as no ethical obstacles, sufficient sources, homogeneity, and no pollution compared to the grafts isolated from fetal ventral midbrain tissue.

The invention belongs to the technical field of regenerative medicine and cell therapy, and particularly relates to a CTLA4. FasL modified liver oval cell and bone marrow mesenchymal stem cell co-transplantation composition and application thereof in liver disease treatment. The invention provides a co-transplantation composition of CTLA4. FasL modified liver oval cells combined with bone marrow mesenchymal stem cells. The T cell rejection reaction is inhibited through the hexamer synergistic effect of the fusion protein CTLA4. FasL, and meanwhile the liver microenvironment is rapidly improved through the paracrine effect of BMSCs. Experiments prove that the composition significantly improves the transplanted cell colonization rate and the liver function recovery speed, and provides a new scheme for treatment of hepatic failure.

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines / regimen or preparatory regimens.

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof. In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

To provide a bornavirus vector that improves the proliferative potential, engraftment efficiency, and expression of a target gene in transplanted cells, and further provide a recombinant virus comprising RNA encoded by the bornavirus vector, cells infected with the recombinant virus, and a pharmaceutical composition comprising the cells.SOLUTION: A bornavirus vector comprising a nucleic acid encoding a growth factor, a recombinant virus comprising RNA encoded by the bornavirus vector, cells into which the nucleic acid has been introduced by infection with the recombinant virus, and a pharmaceutical composition comprising the cells.SELECTED DRAWING: Figure 6

The invention discloses a cell composition and application thereof in preparation of a preparation for treating diabetes mellitus. The cell composition contains pancreatic duct stem cells and functional islet cells formed by chemically inducing the pancreatic duct stem cells to differentiate. According to the invention, rat pancreatic duct stem cells derived from adult rats and functional islet cells chemically induced in vitro are transplanted through hepatic portal veins in a combined manner, so as to treat STZ modeling rat diabetes mellitus. Functional islet cells can directly and timely play a role in reducing blood sugar after entering the body; meanwhile, the transplanted pancreatic stem cells can be continuously amplified and gradually differentiated in vivo to form functional islet cells, so that the hypoglycemic effect is further continuously achieved, and diabetes can be treated for a longer time. The invention provides a method for treating diabetes mellitus through cell transplantation of human beings and other animals, and the method has important theoretical significance and huge social application value and economic value.

Enhancing the fusion ability of transplant cells tends to arrest their proliferation in the production thereof, whereas promoting the proliferation of transplant cells tends to hinder their fusion at a transplantation site. Under such circumstances, the purpose of the present invention is to enable long-term engraftment of transplant cells regardless of concomitant use of immunosuppressants by endowing transplant cells with fusion ability and allowing the transplant cells to exert the fusion ability at a transplantation site at a desired time point, thereby overcoming the problem of graft failure and immune rejection resulting in loss of cells. The present invention provides a cell containing a cell-cell fusion gene as a foreign gene, wherein the cell-cell fusion gene is allowed to be expressed in the presence of an extracellular factor.